Clinical Trial Update: A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of imlunestrant (LY3484356) in premenopausal women with ER-positive, HER2-negative early breast cancer is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Imlunestrant (imlunestrant)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Breast Neoplasms | Phase 2 | Status: NOT_YET_RECRUITING